What are SS-31 and MOTS-c, and what does an SS-31 dosage search ask?
SS-31 is the research name of elamipretide, a tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. The FDA label describes it as a mitochondrial cardiolipin binder and approves it, under the brand name Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg, under accelerated approval [1]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, studied in cells and mice [3].
Searches such as ss-31 peptide dosage or ss31 peptide dosage want a number. For SS-31 there is a labeled one, but it belongs to one indication and one population. For MOTS-c there is none. A stack search adds a third request, how the two fit together, which no source in the library has studied.
What do the elamipretide label and the MOTS-c study report?
The elamipretide label lists 40 mg by subcutaneous injection once daily for patients with Barth syndrome weighing 30 kg or more, with reduced amounts in adults with severe kidney impairment [1]. It supplies the drug as 280 mg in 3.5 mL, or 80 mg/mL, in single-patient-use vials, and it carries a warning about benzyl alcohol in neonates. Elamipretide and its two inactive metabolites leave the body in urine, with about 100% of the dose recovered within 48 hours in patients with normal renal function [1].
The FDA review behind the approval also reports a 40 mg subcutaneous study in 32 healthy volunteers [2]. The library carries a 3.16 hour half-life for SS-31 and uses the labeled presentation as its conversion example [4].
MOTS-c's source is the 2015 discovery paper. In cultured cells it acted on the folate cycle and AMPK; in mice it prevented diet-induced obesity and insulin resistance [3]. No human amount appears, and the library labels MOTS-c research use only with a three-hour estimate [4]. The two peptides share a subject area, not an evidence base.
| Compound | Status | Half-life input | Package example |
|---|---|---|---|
| SS-31 | FDA-labeled presentation | 3.16 h | 10 mg (vendor listing) |
| MOTS-c | Research use only, estimated model data | 3 h | 10 mg (vendor listing) |
How are SS-31 and MOTS-c measured and converted?
Elamipretide comes as a ready solution, so no water is added. The labeled 40 mg divided by 80 mg/mL is 0.5 mL, which corresponds to 50 marks on a U-100 scale [1][5]. The label is the authority on how the product is drawn and given; the arithmetic only shows how the numbers relate.
MOTS-c is a powder. Its 10 mg package example in a hypothetical 2 mL is 5 mg/mL, so 0.5 mL of that solution would hold 2.5 mg, a quarter of the vial [4][5]. Placing the two side by side shows why their volumes cannot be compared: half a millilitre is 40 mg of one and 2.5 mg of the other. The MOTS-c calculator and MOTS-c dosing chart cover the powder; the SS-31 guide covers the labeled solution.
How do people log SS-31 and MOTS-c in PinPoint?
PinPoint tracks prepared solutions and powder vials side by side [6]. An elamipretide vial is entered with its labeled concentration, a MOTS-c vial with its milligram total and water volume, and each injection becomes its own entry with compound, dose, site and pain level [6][4].
Each compound runs on its own schedule, daily for one and three or five times weekly for the other if that is what was entered, with separate reminders [6]. The Home curve models each from its library half-life, 3.16 and three hours. Those are mathematical visualizations of averages and an estimate, and they do not account for individual variation or for how the two might interact [4][6].
Get PinPoint on the App StoreWhat do people ask about SS-31 and MOTS-c?
- Is SS-31 FDA approved?
- Elamipretide, the generic name for SS-31, has an FDA label under the brand name Forzinity for improving muscle strength in Barth syndrome in patients weighing at least 30 kg, under accelerated approval. Research-catalog SS-31 is a different product from the labeled solution.
- What SS-31 dosage does the label list?
- The label lists 40 mg subcutaneously once daily for patients with Barth syndrome weighing 30 kg or more, with adjustments for severe kidney impairment. That figure belongs to the labeled indication.
- How many units is 40 mg of elamipretide?
- At the labeled 80 mg/mL, 40 mg is 0.5 mL, which spans 50 marks on a U-100 scale. The label governs how the product is actually drawn and given.
- Has the ss-31 and mots-c combination been studied?
- No source in the library studied the two together. SS-31 has a label and volunteer data; MOTS-c has a cell and mouse discovery paper.
Where do these facts come from?
Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.
- Elamipretide injection prescribing information (DailyMed)FDA label, sections 1, 2 and 3: indication, labeled dosage and the 280 mg/3.5 mL vial.Retrieved 2026-10-05 · label
- FDA integrated review of elamipretide, 2025FDA review document for the elamipretide application.Retrieved 2026-10-05 · regulatory-review
- Discovery of the mitochondrial-derived peptide MOTS-c, 2015Cell Metab, 2015. Cell and mouse studies of metabolic homeostasis.Retrieved 2026-10-05 · study
- PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
- Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description